BS
Brian Sworder
City Of Hope National Medical Center, University of California, Irvine, Boston University, Boston University School of Medicine
Research areas: Medicine · Hematology · Lymphoma Diagnosis and Treatment · Cancer Genomics and Diagnostics · Acute Lymphoblastic Leukemia research
0000-0002-5902-5507
Employment
-
City Of Hope National Medical Center Assistant Professor2025 - Present
-
University of California, Irvine Assistant Professor in Residence2023 - 2025
Education
- 2004 - 2013
-
Boston University School of Medicine PhD? - 2011
Projects & Funding
-
Molecular characterization of tumor intrinsic mechanisms of resistance to CAR T-cell therapy Lymphoma Research Foundation2021 - 2023
Publications (54)
- A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Save
- Data from A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Save
- Figure S1 from A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Save
- Figure S2 from A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Save
- Figure S3 from A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Save
- Figure S4 from A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Save
- Figure S5 from A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Save
- Table S1 from A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Save
- Table S2 from A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Save
- Supplementary Methods & Figures S1-S5 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors Save
- Supplementary Tables S1-S15 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors Save
- Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma Save
- Prognostic value of circulating tumor DNA (ctDNA) detection by PhasED-Seq after axicabtagene ciloleucel (axi-cel) therapy in relapsed/refractory large B-cell lymphoma (LBCL). Save
- Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response Save
- IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies Save
- Abstract 3252: Circulating tumor DNA (ctDNA) enables enhanced measurable residual disease (MRD) detection and non-invasive clonal profiling in acute myeloid leukemia (AML) Save
- Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma Save
- Clonal Hematopoiesis Underlies Prolonged Cytopenias after Anti-BCMA CAR-T Therapy Save
- Determinants of Post-CAR Myeloid Neoplasms Evolving after Lymphoma Therapy Save
- Anatomic Genetic Heterogeneity Is Uncovered By Concurrent Cell-Free DNA and Tissue Profiling and Predicts Treatment Resistance in Diffuse Large B-Cell Lymphoma Save